Bayer’s counter bid for Schering throws off acquisition opportunities
Bayer's 16 billion euro counter bid for rival German drug company Schering is being criticised by financial analysts because of a lack of overlapping portfolios, precisely the reason the deal could...To view the full article, register now.
Already a subscriber? Click here to view full article